Comparing CPAP Plus High Flow Nasal Oxygen to High Flow Nasal Oxygen Alone for Adults with New Acute Hypoxemic Respiratory Failure in ICU A Randomized Study

What this Trial Is About

De novo hypoxemic acute respiratory failure hARF is a leading cause of admission to intensive care units ICU and is associated with a high risk of death when intubation is needed. Researchers are evaluating whether adding continuous positive airway pressure CPAP to high flow nasal cannula HFNC oxygen therapy can reduce mortality compared to HFNC alone. The trial is a prospective, randomized controlled study focused on patients with de novo acute hypoxemic respiratory failure. Participants will be randomly assigned to one of two groups. One group will receive continuous HFNC oxygen started within one hour after randomization. The other group will receive HFNC combined with CPAP sessions, which provide positive airway pressure to help keep lungs open without added breathing support. The study compares these two oxygenation strategies to see their impact on patient outcomes. During the study, patients will be closely monitored for 90 days to assess mortality and other outcomes such as time to intubation, breathing difficulty, respiratory rate, and tolerance of oxygen therapy. Additional measures include length of ICU and hospital stay, incidence of infections, and number of days free from invasive ventilation or HFNC. Various clinical assessments and blood tests may be performed as needed. The study aims to gather detailed information on safety and effectiveness of the combined CPAP plus HFNC approach over several months.

Impact on Mortality of a Strategy Including Continuous Positive Airway Pressure Plus High Flow Nasal Cannula Oxygen Therapy Versus High Flow Nasal Cannula Oxygen Therapy Alone in Patients With de Novo Acute Hypoxemic Respiratory Failure: a Prospective, Randomized Controlled Trial.